Research

Int J Mol Sci. 2016 Aug; 17(8): 1277.
New Natural Pigment Fraction Isolated from Saw Palmetto: Potential for Adjuvant Therapy of Hepatocellular Carcinoma
Hor-Yue Tan1*, Ning Wang1, Masao Takahashi2, Yigang Feng3, Hongyun Li3 and Yibin Feng1* (*Corresponding author)
  1. LKS Faculty of Medicine, School of Chinese Medicine, The University of Hong Kong.
  2. Heimat Co., Ltd. HeimatBuilding, 1-21-3 Nihonbashi, Chuo-Ku, Tokyo, Japan.
  3. Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University.

Abstract

For the first time, we discovered a small proportion of aqueous fraction from Saw Palmetto apart from the fatty acid-rich fraction exhibited pharmacological activity. Therefore, this study aims to explore the anti-tumor potential of red pigmented aqueous fraction of Saw Palmetto, NYG on human hepatocellular carcinoma and its possible targets. Subcutaneous xenograft and orthotopic implantation models of HCC were used to evaluate the tumor inhibitory effect of NYG. Human hepatocellular carcinoma (HCC) cell lines and human umbilical vein endothelial cells (HUVEC) were used as in vitro model. The mRNA expression was conducted by qPCR. Protein expression was monitored by immunoblotting and immunohistochemistry. Cell migration and blood vessel formation were determined by chamber assay and tube formation assay, respectively. Significant tumor inhibition of NYG in dose-dependent manner was observed on subcutaneous xenograft and orthotopic HCC model. NYG has no direct action on cell viability or VEGF secretion of HCC cells. However, NYG reduced in vitro migration and vessel formation activities of HUVEC cells, as well as in vivo intratumoral neovascularization. NYG attenuated extracellular signal-regulated kinases (ERK) activation in endothelial cells, which may be associated with the suppression of migration and tube formation of HUVEC. NYG suppressed tumor expansion of HCC via inhibiting neovascularization, and may be potential adjuvant treatment for HCC.

Raw materials, OEM and PB option at Heimat Co., Japan Ltd
APCGCT: Asia Pacific Consortium of Gene and Cell Therapy